Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press18710.17650/1726-9776-2013-9-1-62-67PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPROGNOSTIC FACTORS OF PROSTATE CANCER SYSTEMIC PROGRESSION IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMYФАКТОРЫ ПРОГНОЗА СИСТЕМНОГО ПРОГРЕССИРОВАНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ У ПАЦИЕНТОВ С БИОХИМИЧЕСКИМ РЕЦИДИВОМ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИDemeshkoP. D.ДемешкоП. Д.
Belarus
pdemeshko@list.ruKrasnyS. A.КрасныйС. А.
Belarus
pdemeshko@list.ruN.N. Alexandrov National Cancer Center of Belarus, MinskРеспубликанский НПЦ онкологии и медицинской радиологии им. Н.Н. Александрова, Минск300320139162673107201431072014https://oncourology.abvpress.ru/oncur/article/view/187

The impact of different prognostics factors on the probability of development local and systemic relups in patient with biochemical recurrence following prostatectomy was studied. By multivariable analysis, predictors of systemic progression were seminal vesicle invasion (pT3b) (p = 0,005), trigger prostate-specific antigen level greater than 2 ng/mL (p = 0,03), prostate-specific antigen doubling time of 6 months or less (p = 0,002) and prostate-specific antigen velocity greater than 0,1 ng/mL per month (p < 0,0001). The rate of systemic progression in patient with not greater than one unfavorable predictor was 6,3 %, with two or greater predictors – 88,9 % (p < 0,001).

Изучалось влияние различных прогностических факторов на вероятность выявления изолированного местного рецидива или системного прогрессирования рака предстательной железы у пациентов с биохимическим рецидивом после радикальной простатэктомии. В мультивариантном анализе наличие инвазии семенных пузырьков по данным послеоперационного морфологического исследования, уровень простатспецифического антигена (ПСА) на момент проведения обследования > 2 нг/мл, скорость прироста ПСА > 0,1 нг/мл в месяц и время его удвоения ≤ 6 мес являются независимыми факторами, ассоциированными с высокой вероятностью наличия системного распространения заболевания у пациентов с бессимптомным повышением ПСА после радикальной простатэктомии (p < 0,05). Частота выявления системного распространения процесса при наличии двух и более неблагоприятных факторов составила 88,9 %, при наличии не более одного фактора – 6,3 % (p < 0,001).

prostate cancerbiochemical recurrenceradical prostatectomyрак предстательной железыбиохимический рецидиврадикальная простатэктомия1. Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843–48.Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843–48.2. Bill-Axelson A., Holmberg L., Ruutu M. et al. Scandinavian prostate cancer group study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84.Bill-Axelson A., Holmberg L., Ruutu M. et al. Scandinavian prostate cancer group study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84.3. Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.4. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–97.Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–97.5. Bolla M., van Poppel H., Collette L. et al. European organization for research and treatment of cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485): 572–78.Bolla M., van Poppel H., Collette L. et al. European organization for research and treatment of cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485): 572–78.6. Carey B.M. Imaging for prostate cancer. Clin Oncol 2005;17:553–59.Carey B.M. Imaging for prostate cancer. Clin Oncol 2005;17:553–59.7. Laufer M., Pound C.R., Carducci M.A. et al. Management of patients with rising prostate-specificantigen after radical prostatectomy. Urology 2000;55:309–15.Laufer M., Pound C.R., Carducci M.A. et al. Management of patients with rising prostate-specificantigen after radical prostatectomy. Urology 2000;55:309–15.8. Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358–68.Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358–68.9. Aus G., Heidenreich A., Bolla M. et al. EAUguidelines on prostate cancer. Eur Urol 2005;48:546–551.Aus G., Heidenreich A., Bolla M. et al. EAUguidelines on prostate cancer. Eur Urol 2005;48:546–551.10. Stephenson A.J., Shariat S.F., Zelefsky M.J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.Stephenson A.J., Shariat S.F., Zelefsky M.J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.11. Warren K.S., Chodak G.W., See W.A. et al. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? J Urol 2006; 176 (1):70–4.Warren K.S., Chodak G.W., See W.A. et al. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? J Urol 2006; 176 (1):70–4.12. Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41.Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41.13. Trock B.J., Han M., Freedland S.J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299 (23):2760–69.Trock B.J., Han M., Freedland S.J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299 (23):2760–69.14. Lee A.K., D’Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23 (32):8192–97.Lee A.K., D’Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23 (32):8192–97.15. Freedland S.J., Humphreys E.B., Mangold L.A. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–39.Freedland S.J., Humphreys E.B., Mangold L.A. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–39.